Figure 2

(A) Chemical structures of the 4 hits identified from the Biacore screening and (B) selection of the preclinical candidate (GLYN122) from the analogue expansion of one of the hit compounds (GLYN026) derived from two adjacent chemical fragments obtained from virtual protein surface scanning.